We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-13%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$46B
AUM Growth
-$5.82B
(-11%)
Cap. Flow
+$1.91B
Cap. Flow
% of AUM
4.16%
Top 10 Holdings %
Top 10 Hldgs %
16.37%
Holding
3,033
New
111
Increased
2,420
Reduced
427
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$127M |
| 2 |
Cigna
CI
|
+$54M |
| 3 |
CVS Health
CVS
|
+$38.8M |
| 4 |
Marathon Petroleum
MPC
|
+$28.9M |
| 5 |
Diamondback Energy
FANG
|
+$19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$124M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$100M |
| 3 |
PX
Praxair Inc
PX
|
+$80.2M |
| 4 |
COL
Rockwell Collins
COL
|
+$43.7M |
| 5 |
ANDV
Andeavor
ANDV
|
+$41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.95% |
| 2 | Financials | 15.85% |
| 3 | Healthcare | 14.41% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Industrials | 10.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RETA
1851
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.4M | ﹤0.01% |
24,995
+8,189
| +49% | +$500K |
|
1852
CNA Financial
CNA
$14.2B
| $1.4M | ﹤0.01% |
31,621
+301
| +1% | +$13.6K |
|
1853
Editas Medicine
EDIT
$445M
| $1.39M | ﹤0.01% |
61,032
+20,080
| +49% | +$546K |
|
1854
CEVA Inc
CEVA
$992M
| $1.39M | ﹤0.01% |
62,803
+10,550
| +20% | +$264K |
|
|
AIMT
1855
DELISTED
Aimmune Therapeutics
AIMT
| $1.39M | ﹤0.01% |
57,947
+18,916
| +48% | +$489K |
|
|
IBTX
1856
DELISTED
Independent Bank Group, Inc.
IBTX
| $1.38M | ﹤0.01% |
30,212
+8,900
| +42% | +$505K |
|
1857
MarineMax
HZO
$776M
| $1.38M | ﹤0.01% |
75,236
+9,051
| +14% | +$189K |
|
1858
Cactus
WHD
$5.5B
| $1.38M | ﹤0.01% |
50,184
+17,296
| +53% | +$566K |
|
1859
John B. Sanfilippo & Son
JBSS
$976M
| $1.37M | ﹤0.01% |
24,679
+4,281
| +21% | +$276K |
|
|
EGRX
1860
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $1.37M | ﹤0.01% |
34,105
+7,637
| +29% | +$394K |
|
1861
Stride
LRN
$3.4B
| $1.37M | ﹤0.01% |
55,266
+16,129
| +41% | +$344K |
|
1862
Donnelley Financial Solutions
DFIN
$1.19B
| $1.37M | ﹤0.01% |
97,581
+16,499
| +20% | +$264K |
|
|
FG
1863
DELISTED
FGL Holdings Ordinary Shares
FG
| $1.37M | ﹤0.01% |
205,248
+65,453
| +47% | +$508K |
|
|
VGR
1864
DELISTED
Vector Group Ltd.
VGR
| $1.36M | ﹤0.01% |
207,263
+63,617
| +44% | +$537K |
|
1865
American Public Education
APEI
$931M
| $1.36M | ﹤0.01% |
47,833
+8,068
| +20% | +$247K |
|
1866
Cohen & Steers
CNS
$4.34B
| $1.36M | ﹤0.01% |
39,608
+9,157
| +30% | +$339K |
|
|
BHVN
1867
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $1.36M | ﹤0.01% |
36,745
+12,587
| +52% | +$454K |
|
1868
Helios Technologies
HLIO
$2.72B
| $1.35M | ﹤0.01% |
40,764
+12,307
| +43% | +$520K |
|
|
HMHC
1869
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $1.35M | ﹤0.01% |
152,315
+45,546
| +43% | +$360K |
|
1870
Workiva
WK
$3.38B
| $1.35M | ﹤0.01% |
37,595
+12,454
| +50% | +$438K |
|
1871
Insmed
INSM
$28.7B
| $1.35M | ﹤0.01% |
102,732
+32,813
| +47% | +$524K |
|
|
DMC
1872
Del Monte Corp
DMC
$1.41B
| $1.34M | ﹤0.01% |
47,578
+13,689
| +40% | +$429K |
|
|
HDP
1873
DELISTED
Hortonworks, Inc.
HDP
| $1.34M | ﹤0.01% |
93,089
+31,954
| +52% | +$551K |
|
|
LGF.B
1874
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $1.34M | ﹤0.01% |
90,025
+1,092
| +1% | +$19.7K |
|
1875
Argan
AGX
$8.28B
| $1.34M | ﹤0.01% |
35,315
+6,335
| +22% | +$268K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2018 Portfolio in Review
As of Q4 2018, RhumbLine Advisers held 3,033 positions worth $46B, down 11% from $51.8B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
RhumbLine Advisers deployed $1.91B of net new capital in Q4 2018, opening 111 new positions and adding to 2,420 existing holdings. Its largest new stake was Linde: 805,738 shares worth $126M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $30.2M trimmed.
- RhumbLine Advisers's largest Q4 2018 buy was Linde: 805,738 shares worth $126M.
- RhumbLine Advisers added most to Cigna in Q4 2018, an estimated $54M increase.
- RhumbLine Advisers's biggest Q4 2018 reduction was Apple, cutting an estimated $30.2M.
- RhumbLine Advisers fully exited Aetna Inc in Q4 2018, selling an estimated $124M.
- RhumbLine Advisers's ten largest holdings make up 16% of its $46B portfolio in Q4 2018.
- RhumbLine Advisers opened 111 new positions and closed 53 in Q4 2018.
- RhumbLine Advisers's portfolio value fell 11% quarter-over-quarter to $46B.
Based on RhumbLine Advisers's 13F filing for Q4 2018, filed 31 Jan 2019.